Clinical Trials Directory

Trials / Unknown

UnknownNCT03639519

A Trial to Assess the Impact of Ascorbic Acid on Cardiac Surgeries Outcomes and Complications''

'A Prospective Randomized Trial to Assess the Impact of Ascorbic Acid on Outcomes and Complications Post Cardiac Surgeries''

Status
Unknown
Phase
Phase 4
Study type
Interventional
Enrollment
100 (estimated)
Sponsor
El-Galaa Military Medical Complex · Other Government
Sex
All
Age
21 Years
Healthy volunteers
Not accepted

Summary

this study is evaluating the safety and efficacy of ascorbic acid as a drug that can decrease inflammatory complications post surgical in addition to its impact on decreasing risk of arrhythmia and total opioid administration post operative

Detailed description

The study will include two arm of patients who are scheduled for elective cardiac surgery, either coronary artery bypass grafting (CABG) or Valvular replacement First arm: Patients will take 2 g orally ascorbic acid effervescent tablets the night before cardiac surgery, then 1 g twice daily for 5 days after surgery in addition to their traditional medical care. Second arm: will not be given ascorbic acid , instead a placebo 9orange carbonated beverage) will be used, and will be given the rest of traditional medical care provided to the first arm. Inflammatory markers C- reactive protein (CRP), erythrocyte sedimentation rate (ESR) and differential total leukocytic count (TLC), serum urea and creatinine, ALT, AST, CK-mb, CK-Total, aPTT, INR, Hemoglobin, platelet count, will be assessed on day 0, 1,2,4,6 postoperative in both arms.

Conditions

Interventions

TypeNameDescription
DRUGAscorbic Acid 500Mg Chew TabAscorbic acid will be administered at the night before surgery and will be continued for five days
OTHERCarbonated orange beverageThe carbonated orange beverage will be administered at the night before surgery and will be continued for five days

Timeline

Start date
2018-04-15
Primary completion
2019-04-15
Completion
2019-08-15
First posted
2018-08-21
Last updated
2018-08-21

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT03639519. Inclusion in this directory is not an endorsement.